Nika Pharmaceuticals, Inc (NIKA) Common Equity (2021 - 2023)
Nika Pharmaceuticals' (NIKA) quarterly Common Equity came in at -$17316.0 in Q4 2023, little changed YoY from -$17316.0 in Q4 2022, and up 76.86% on a QoQ basis from -$74835.0 in Q3 2023.
Nika Pharmaceuticals, Inc (NIKA) Common Equity (2021 - 2023) Analysis & Trends
Nika Pharmaceuticals (NIKA) has 3 years of Common Equity data on file, last reported at -$17316.0 in Q4 2023.
- Quarterly Common Equity changed 0.0% year-over-year to -$17316.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$17316.0 (changed 0.0% YoY) and the FY2023 annual result came in at -$17316.0, changed 0.0% from the prior year.
- Common Equity rose to -$17316.0 in Q4 2023, from -$74835.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $4073.0 in Q2 2022 to a low of -$74835.0 in Q3 2023.
- A 3-year average of -$23781.2 and a median of -$17468.0 in 2021 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 123.12% — and 2023, when it sank 44540.96%.
- Tracing NIKA's Common Equity over 3 years: stood at -$23619.0 in 2021, then rose by 26.69% to -$17316.0 in 2022, then changed by 0.0% to -$17316.0 in 2023.
- The last three Common Equity figures came in at -$17316.0 (Q4 2023), -$74835.0 (Q3 2023), and -$64692.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -17,316.00 |
| Sep 30, 2023 | -74,835.00 |
| Jun 30, 2023 | -64,692.00 |
| Mar 31, 2023 | -36,886.00 |
| Dec 31, 2022 | -17,316.00 |
| Sep 30, 2022 | -2,266.00 |
| Jun 30, 2022 | 4,073.00 |
| Mar 31, 2022 | 83.00 |
| Dec 31, 2021 | -23,619.00 |
| Sep 30, 2021 | -20,319.00 |
| Jun 30, 2021 | -17,620.00 |
| Mar 31, 2021 | -14,661.00 |